James Ballenger to Aged
This is a "connection" page, showing publications James Ballenger has written about Aged.
Connection Strength
0.209
-
Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
Score: 0.020
-
Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2.
Score: 0.013
-
Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7.
Score: 0.012
-
Discussion and overview: what can we learn if we view panic disorder across the life span and across different presentations and contexts? Bull Menninger Clin. 1997; 61(2 Suppl A):A95-102.
Score: 0.011
-
Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
Score: 0.011
-
Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7.
Score: 0.011
-
Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2.
Score: 0.010
-
Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8.
Score: 0.009
-
Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4.
Score: 0.009
-
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
Score: 0.009
-
Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34.
Score: 0.009
-
Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
Score: 0.009
-
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
Score: 0.009
-
Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
Score: 0.008
-
Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9.
Score: 0.008
-
Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8.
Score: 0.007
-
Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
Score: 0.007
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
Score: 0.006
-
Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
Score: 0.006
-
Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84.
Score: 0.005
-
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
Score: 0.003
-
Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8.
Score: 0.003
-
Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
Score: 0.003
-
A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
Score: 0.002
-
Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
Score: 0.002
-
Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58.
Score: 0.002
-
Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
Score: 0.002
-
Tetrahydrobiopterin levels in cerebrospinal fluid of affectively ill patients. Lancet. 1983 Jul 02; 2(8340):55-6.
Score: 0.001
-
Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6.
Score: 0.001
-
Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31.
Score: 0.001
-
Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
Score: 0.001
-
Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9.
Score: 0.001
-
Plasma and CSF MHPG in normals [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):86-7.
Score: 0.001
-
Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94.
Score: 0.001